Literature DB >> 8612235

Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein.

O Schwartz1, V Maréchal, S Le Gall, F Lemonnier, J M Heard.   

Abstract

Like other pathogenic viruses, HIV-1 down-modulates surface expression of major histocompatibility complex class I (MHC-I) molecules in infected cells, thus impairing lysis by cytotoxic T lymphocytes. We have observed that this phenomenon depends on the expression of Nef. nef is an early gene of primate lentiviruses, which is necessary for maintaining high virus loads and inducing AIDS. Nef is not necessary for viral replication in vitro and stimulates the endocytosis of CD4. We show that the expression of MHC-I at the surface of lymphoid, monocytic and epithelial cells was reduced in the presence of Nef protein from various HIV-1 strains. Whereas MHC-I protein synthesis and transport through the endoplasmic reticulum and cis Golgi apparatus occurred normally in Nef(+) cells, surface MHC-I molecules were rapidly internalized, accumulated in endosomal vesicles and were degraded. The stimulation of MHC-I endocytosis by Nef represents a previously undocumented viral mechanism for evading the immune response.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8612235     DOI: 10.1038/nm0396-338

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  435 in total

1.  Weak anti-HIV CD8(+) T-cell effector activity in HIV primary infection.

Authors:  M Dalod; M Dupuis; J C Deschemin; C Goujard; C Deveau; L Meyer; N Ngo; C Rouzioux; J G Guillet; J F Delfraissy; M Sinet; A Venet
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

2.  Mechanism for down-regulation of CD28 by Nef.

Authors:  T Swigut; N Shohdy; J Skowronski
Journal:  EMBO J       Date:  2001-04-02       Impact factor: 11.598

3.  Mobilization of MHC class I molecules from late endosomes to the cell surface following activation of CD34-derived human Langerhans cells.

Authors:  P A MacAry; M Lindsay; M A Scott; J I Craig; J P Luzio; P J Lehner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

4.  HIV-1 Nef protein binds to the cellular protein PACS-1 to downregulate class I major histocompatibility complexes.

Authors:  V Piguet; L Wan; C Borel; A Mangasarian; N Demaurex; G Thomas; D Trono
Journal:  Nat Cell Biol       Date:  2000-03       Impact factor: 28.824

5.  Mutation of a conserved residue (D123) required for oligomerization of human immunodeficiency virus type 1 Nef protein abolishes interaction with human thioesterase and results in impairment of Nef biological functions.

Authors:  L X Liu; N Heveker; O T Fackler; S Arold; S Le Gall; K Janvier; B M Peterlin; C Dumas; O Schwartz; S Benichou; R Benarous
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 6.  Human gamma delta T lymphocytes in HIV disease: effector functions and control by natural killer cell receptors.

Authors:  M L Gougeon; F Poccia; S Boullier
Journal:  Springer Semin Immunopathol       Date:  2000

7.  A cytomegalovirus glycoprotein re-routes MHC class I complexes to lysosomes for degradation.

Authors:  U Reusch; W Muranyi; P Lucin; H G Burgert; H Hengel; U H Koszinowski
Journal:  EMBO J       Date:  1999-02-15       Impact factor: 11.598

8.  HIV-1 Nef impairs MHC class II antigen presentation and surface expression.

Authors:  P Stumptner-Cuvelette; S Morchoisne; M Dugast; S Le Gall; G Raposo; O Schwartz; P Benaroch
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

9.  Free major histocompatibility complex class I heavy chain is preferentially targeted for degradation by human T-cell leukemia/lymphotropic virus type 1 p12(I) protein.

Authors:  J M Johnson; C Nicot; J Fullen; V Ciminale; L Casareto; J C Mulloy; S Jacobson; G Franchini
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

10.  PACS-1 binding to adaptors is required for acidic cluster motif-mediated protein traffic.

Authors:  C M Crump; Y Xiang; L Thomas; F Gu; C Austin; S A Tooze; G Thomas
Journal:  EMBO J       Date:  2001-05-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.